125 related articles for article (PubMed ID: 10930054)
1. Evidence of enhanced iron excretion during systemic phosphorothioate oligodeoxynucleotide treatment.
Mata JE; Bishop MR; Tarantolo SR; Angel CR; Swanson SA; Iversen PL
J Toxicol Clin Toxicol; 2000; 38(4):383-7. PubMed ID: 10930054
[TBL] [Abstract][Full Text] [Related]
2. Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome: initial results of a phase I trial.
Bayever E; Iversen PL; Bishop MR; Sharp JG; Tewary HK; Arneson MA; Pirruccello SJ; Ruddon RW; Kessinger A; Zon G
Antisense Res Dev; 1993; 3(4):383-90. PubMed ID: 8155979
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies.
Bishop MR; Iversen PL; Bayever E; Sharp JG; Greiner TC; Copple BL; Ruddon R; Zon G; Spinolo J; Arneson M; Armitage JO; Kessinger A
J Clin Oncol; 1996 Apr; 14(4):1320-6. PubMed ID: 8648390
[TBL] [Abstract][Full Text] [Related]
4. Ex vivo treatment of bone marrow with phosphorothioate oligonucleotide OL(1)p53 for autologous transplantation in acute myelogenous leukemia and myelodysplastic syndrome.
Bishop MR; Jackson JD; Tarantolo SR; O'Kane-Murphy B; Iversen PL; Bayever E; Joshi SM; Sharp JG; Pierson JL; Warkentin PI; Armitage JO; Kessinger A
J Hematother; 1997 Oct; 6(5):441-6. PubMed ID: 9368180
[TBL] [Abstract][Full Text] [Related]
5. Distribution and excretion of a phosphorothioate oligonucleotide in rats with experimentally induced renal injury.
Masarjian L; de Peyster A; Levin AA; Monteith DK
Oligonucleotides; 2004; 14(4):299-310. PubMed ID: 15665597
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and metabolism of an oligodeoxynucleotide phosphorothioate (GEM91) in cynomolgus monkeys following intravenous infusion.
Grindel JM; Musick TJ; Jiang Z; Roskey A; Agrawal S
Antisense Nucleic Acid Drug Dev; 1998 Feb; 8(1):43-52. PubMed ID: 9512095
[TBL] [Abstract][Full Text] [Related]
7. Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer.
Rudin CM; Holmlund J; Fleming GF; Mani S; Stadler WM; Schumm P; Monia BP; Johnston JF; Geary R; Yu RZ; Kwoh TJ; Dorr FA; Ratain MJ
Clin Cancer Res; 2001 May; 7(5):1214-20. PubMed ID: 11350886
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and tolerability of intravenous trecovirsen (GEM 91), an antisense phosphorothioate oligonucleotide, in HIV-positive subjects.
Séréni D; Tubiana R; Lascoux C; Katlama C; Taulera O; Bourque A; Cohen A; Dvorchik B; Martin RR; Tournerie C; Gouyette A; Schechter PJ
J Clin Pharmacol; 1999 Jan; 39(1):47-54. PubMed ID: 9987700
[TBL] [Abstract][Full Text] [Related]
9. Toxicity and toxicokinetics of a phosphorothioate oligonucleotide against the c-myc oncogene in cynomolgus monkeys.
Webb MS; Tortora N; Cremese M; Kozlowska H; Blaquiere M; Devine DV; Kornbrust DJ
Antisense Nucleic Acid Drug Dev; 2001 Jun; 11(3):155-63. PubMed ID: 11446591
[TBL] [Abstract][Full Text] [Related]
10. A phase I trial of c-Raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer.
Cunningham CC; Holmlund JT; Schiller JH; Geary RS; Kwoh TJ; Dorr A; Nemunaitis J
Clin Cancer Res; 2000 May; 6(5):1626-31. PubMed ID: 10815879
[TBL] [Abstract][Full Text] [Related]
11. A phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and acute myeloid leukemia.
Klisovic RB; Stock W; Cataland S; Klisovic MI; Liu S; Blum W; Green M; Odenike O; Godley L; Burgt JV; Van Laar E; Cullen M; Macleod AR; Besterman JM; Reid GK; Byrd JC; Marcucci G
Clin Cancer Res; 2008 Apr; 14(8):2444-9. PubMed ID: 18413836
[TBL] [Abstract][Full Text] [Related]
12. In vivo metabolic profile of a phosphorothioate oligodeoxyribonucleotide.
Temsamani J; Roskey A; Chaix C; Agrawal S
Antisense Nucleic Acid Drug Dev; 1997 Jun; 7(3):159-65. PubMed ID: 9212906
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expression.
Geary RS; Leeds JM; Fitchett J; Burckin T; Truong L; Spainhour C; Creek M; Levin AA
Drug Metab Dispos; 1997 Nov; 25(11):1272-81. PubMed ID: 9351904
[TBL] [Abstract][Full Text] [Related]
14. Biodistribution, stability, and antiviral efficacy of liposome-entrapped phosphorothioate antisense oligodeoxynucleotides in ducks for the treatment of chronic duck hepatitis B virus infection.
Soni PN; Brown D; Saffie R; Savage K; Moore D; Gregoriadis G; Dusheiko GM
Hepatology; 1998 Nov; 28(5):1402-10. PubMed ID: 9794928
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of phosphorothioate antisense oligodeoxynucleotides.
Geary RS; Yu RZ; Levin AA
Curr Opin Investig Drugs; 2001 Apr; 2(4):562-73. PubMed ID: 11566019
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics, tissue distribution, and stability of antisense oligodeoxynucleotide phosphorothioate ISIS 3466 in mice.
Saijo Y; Perlaky L; Wang H; Busch H
Oncol Res; 1994; 6(6):243-9. PubMed ID: 7865900
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of an antisense phosphorothioate oligodeoxynucleotide against rev from human immunodeficiency virus type 1 in the adult male rat following single injections and continuous infusion.
Iversen PL; Mata J; Tracewell WG; Zon G
Antisense Res Dev; 1994; 4(1):43-52. PubMed ID: 8061515
[TBL] [Abstract][Full Text] [Related]
18. Phase I and phase II safety and efficacy trial of intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302) for the prevention of acute allograft rejection.
Kahan BD; Stepkowski S; Kilic M; Katz SM; Van Buren CT; Welsh MS; Tami JA; Shanahan WR
Transplantation; 2004 Sep; 78(6):858-63. PubMed ID: 15385805
[TBL] [Abstract][Full Text] [Related]
19. Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease.
Yacyshyn BR; Chey WY; Goff J; Salzberg B; Baerg R; Buchman AL; Tami J; Yu R; Gibiansky E; Shanahan WR;
Gut; 2002 Jul; 51(1):30-6. PubMed ID: 12077088
[TBL] [Abstract][Full Text] [Related]
20. c-raf-1 depletion and tumor responses in patients treated with the c-raf-1 antisense oligodeoxynucleotide ISIS 5132 (CGP 69846A).
O'Dwyer PJ; Stevenson JP; Gallagher M; Cassella A; Vasilevskaya I; Monia BP; Holmlund J; Dorr FA; Yao KS
Clin Cancer Res; 1999 Dec; 5(12):3977-82. PubMed ID: 10632328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
